Premarin (Conjugated Equine Estrogens) 0.3 mg to 1.25 mg Tablets: Prescription Estrogen Replacement for Menopausal Symptoms, Vaginal Atrophy, and Osteoporosis Prevention

Reviewed by the Lucas Clinic Medical Team | Updated May 2026

Premarin (conjugated equine estrogens, abbreviated CEE) is a hormone replacement medicine derived from the urine of pregnant mares — its name is a contraction of pregnant mare's urine. It was first approved by the FDA in 1942 and remains one of the world's most widely prescribed menopausal hormone therapies. Premarin contains a mixture of conjugated estrogens — primarily estrone sulfate (approximately 50–60%) along with equilin, equilenin, and other conjugated equine estrogen fractions — that collectively exert estrogenic activity at estrogen receptors throughout the body. This mixture is biologically active in humans and has been the subject of more long-term clinical trial data (including the Women's Health Initiative studies) than virtually any other hormone therapy product.

Premarin is used in menopausal and postmenopausal women for the management of moderate-to-severe vasomotor symptoms (hot flushes, night sweats), genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs), and prevention of postmenopausal osteoporosis. It is not indicated for the treatment of cardiovascular disease or cognitive decline. Premarin is prescription-only in the US and all comparable markets — no OTC estrogen tablet is approved in the US.

What Is Premarin?

Premarin's active constituents are sulfated estrogens of equine origin. Following oral administration, the conjugated estrogens are absorbed from the gastrointestinal tract, undergo hepatic first-pass metabolism, and are distributed systemically. Estrone is the dominant circulating estrogen in postmenopausal women, and Premarin raises systemic estrone and estradiol levels, relieving the estrogen deficiency that underlies menopausal symptoms.

A critical prescribing consideration: women with an intact uterus must receive concomitant progestogen therapy alongside estrogen. Unopposed estrogen therapy (estrogen without progestogen) in women with a uterus is associated with a significantly increased risk of endometrial hyperplasia and endometrial carcinoma. Adding a progestogen (e.g., medroxyprogesterone acetate, progesterone, norethindrone) prevents endometrial stimulation. Women who have had a hysterectomy do not require progestogen and may use estrogen-only therapy. Premarin combined with medroxyprogesterone acetate (MPA) is available as a fixed-combination product called Prempro (for continuous combined HRT) and Premphase (sequential HRT).

Prescription vs. Over-the-Counter Status

Premarin is prescription-only in the US, UK, and EU. No OTC estrogen tablet is approved in the US, UK, or EU. The FDA does not approve OTC hormone replacement therapies for systemic estrogen use. Compounded bio-identical estrogen products available from compounding pharmacies require a prescription and are not FDA-approved formulations — their safety and efficacy are not individually evaluated. Women in the UK can access some estrogen-containing vaginal products OTC for localised symptoms of vaginal atrophy (e.g., Gina — estradiol 10 mcg vaginal tablets — obtained OTC from pharmacies with pharmacist consultation for women over 45 without a uterus or taking systemic HRT), but oral/systemic estrogen therapy requires prescription in all markets.

Available Strengths and Forms

Premarin tablets are available in five oral strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg. The 0.625 mg dose is the most commonly prescribed starting dose for vasomotor symptoms. The lowest effective dose should be prescribed for the shortest duration consistent with treatment goals. In addition to oral tablets, Premarin is available as Premarin vaginal cream (0.625 mg/g cream) for topical application to the vaginal epithelium for genitourinary syndrome of menopause — this formulation is applied intravaginally and has lower systemic absorption than oral tablets. Systemic HRT is also available in other estrogen formulations (estradiol tablets, patches, gels, sprays) which some prescribers prefer for their more predictable pharmacokinetics and lower thrombotic risk vs. oral CEE.

Price of Premarin

Premarin oral tablets (0.625 mg, 30 tablets) typically retail at US pharmacies for approximately $100–$140 without insurance. Brand Premarin has no FDA-approved generic equivalent in the US — it has never lost exclusivity to an approved generic (oral conjugated equine estrogens uniquely require equine source materials making exact generic replication complex). The Premarin vaginal cream (28.4 g tube) retails for approximately $240–$270. With insurance or manufacturer coupon (Pfizer/Wyeth makes Premarin), costs may be significantly reduced. Patients should consult GoodRx and the Pfizer savings programme for discount options.

Frequently Asked Questions

Does Premarin increase breast cancer risk?

The Women's Health Initiative (WHI) provided the most extensive data. The WHI estrogen-alone arm (Premarin in women with hysterectomy) showed no increase in breast cancer risk — slightly fewer breast cancer diagnoses in the estrogen-only group compared to placebo, in fact. The combination arm (Premarin + MPA = Prempro) showed a small increase in breast cancer risk with long-term use (approximately 8 extra cases per 10,000 women per year). Current guidelines suggest the breast cancer risk associated with HRT is comparable to or less than risks from other common lifestyle factors (obesity, alcohol consumption, physical inactivity) and that the absolute risk increase for most patients is modest. Individual risk-benefit discussion with the prescriber remains essential.

Can Premarin be used in women who have had a hysterectomy?

Yes. Women who have had a hysterectomy (surgical removal of the uterus) do not have a uterine lining to stimulate and therefore do not require concomitant progestogen therapy. Premarin estrogen-only therapy (without progestogen) is appropriate for these patients. In fact, the WHI estrogen-alone arm demonstrated a somewhat different risk-benefit profile compared to the combined arm — without the additional progestogen-related breast cancer risk observed in women with an intact uterus using combined HRT. The prescriber should still individually assess cardiovascular, thrombotic, and breast cancer risk factors even in women who have had a hysterectomy.

How long should Premarin be taken?

The FDA recommends using HRT (including Premarin) at the lowest effective dose for the shortest duration consistent with treatment goals. In practice, many women use systemic HRT for 3–5 years for vasomotor symptom management, then taper off as symptoms remit naturally. Some women with severe persistent symptoms may use HRT for longer under ongoing medical supervision. Annual review of ongoing HRT need is recommended. For osteoporosis prevention, longer durations may be appropriate but osteoporosis-specific agents (bisphosphonates, denosumab) are generally preferred for that indication after individual fracture risk assessment. HRT should not be stopped abruptly — gradual dose reduction minimises rebound symptom recurrence.

← Back to Women's Hormone Medications